Vaccines, Synthetic

"Vaccines, Synthetic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.

Descriptor ID	D014614
MeSH Number(s)	D12.776.828.868 D20.215.894.865 D23.050.865
Concept/Terms	Vaccines, Synthetic Vaccines, Synthetic Synthetic Vaccines Synthetic Immunogens Immunogens, Synthetic Semisynthetic Vaccines Semisynthetic Vaccines Vaccines, Semisynthetic Antigens, Synthetic Antigens, Synthetic Synthetic Antigens Molecular Vaccines Molecular Vaccines Vaccines, Molecular Vaccines, Chemical Chemical Vaccines Vaccines, Recombinant Vaccines, Recombinant Recombinant Vaccines

Below are MeSH descriptors whose meaning is more general than "Vaccines, Synthetic".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Recombinant Proteins [D12.776.828]
Vaccines, Synthetic [D12.776.828.868]
Complex Mixtures [D20]
Biological Products [D20.215]
Vaccines [D20.215.894]
Vaccines, Synthetic [D20.215.894.865]
Biological Factors [D23]
Antigens [D23.050]
Vaccines, Synthetic [D23.050.865]

Below are MeSH descriptors whose meaning is more specific than "Vaccines, Synthetic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Vaccines, Synthetic" by people in this website by year, and whether "Vaccines, Synthetic" was a major or minor topic of these publications.

Bar chart showing 28 publications over 14 distinct years, with a maximum of 4 publications in 2002 and 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2000	0	1	1
2002	0	4	4
2003	2	1	3
2005	1	3	4
2006	0	3	3
2007	1	1	2
2010	0	1	1
2011	0	2	2
2015	0	1	1
2016	1	0	1
2017	0	2	2
2020	1	0	1
2021	0	1	1
2022	1	1	2

Below are the most recent publications written about "Vaccines, Synthetic" by people in Profiles.

Sievers BL, Chakraborty S, Xue Y, Gelbart T, Gonzalez JC, Cassidy AG, Golan Y, Prahl M, Gaw SL, Arunachalam PS, Blish CA, Boyd SD, Davis MM, Jagannathan P, Nadeau KC, Pulendran B, Singh U, Scheuermann RH, Frieman MB, Vashee S, Wang TT, Tan GS. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022 03 02; 14(634):eabn7842.

View in: PubMed
Ndeupen S, Bouteau A, Herbst C, Qin Z, Jacobsen S, Powers NE, Hutchins Z, Kurup D, Diba LZ, Watson M, Ramage H, Igyártó BZ. Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses. PLoS Pathog. 2022 01; 18(1):e1010255.

View in: PubMed
Kurup D, Schnell MJ. SARS-CoV-2 vaccines - the biggest medical research project of the 21st century. Curr Opin Virol. 2021 08; 49:52-57.

View in: PubMed
Lederer K, Castaño D, Gómez Atria D, Oguin TH, Wang S, Manzoni TB, Muramatsu H, Hogan MJ, Amanat F, Cherubin P, Lundgreen KA, Tam YK, Fan SHY, Eisenlohr LC, Maillard I, Weissman D, Bates P, Krammer F, Sempowski GD, Pardi N, Locci M. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity. 2020 12 15; 53(6):1281-1295.e5.

View in: PubMed
Haley SL, Tzvetkov EP, Meuwissen S, Plummer JR, McGettigan JP. Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis. J Virol. 2017 Apr 15; 91(8).

View in: PubMed
da Fontoura Budaszewski R, Hudacek A, Sawatsky B, Krämer B, Yin X, Schnell MJ, von Messling V. Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens. J Virol. 2017 Apr 15; 91(8).

View in: PubMed
Snook AE, Baybutt TR, Hyslop T, Waldman SA. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. Hum Gene Ther Methods. 2016 Dec; 27(6):238-250.

View in: PubMed
Kandeil A, Moatasim Y, Gomaa MR, Shehata MM, El-Shesheny R, Barakat A, Webby RJ, Ali MA, Kayali G. Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. Vaccine. 2016 Jan 04; 34(2):218-224.

View in: PubMed
Blaney JE, Wirblich C, Papaneri AB, Johnson RF, Myers CJ, Juelich TL, Holbrook MR, Freiberg AN, Bernbaum JG, Jahrling PB, Paragas J, Schnell MJ. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol. 2011 Oct; 85(20):10605-16.

View in: PubMed
Mustafa W, Al-Saleem FH, Nasser Z, Olson RM, Mattis JA, Simpson LL, Schnell MJ. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine. 2011 Jun 20; 29(28):4638-45.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement